drugset / Trial / NCT00002960
SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)
Treatment
Summary
RATIONALE: Giving the p53 gene for ovarian, fallopian tube, or peritoneal cancer may inhibit tumor growth. Giving the gene directly into the peritoneum may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of SCH-58500 in treating patients who have recurrent or persistent primary ovarian, fallopian tube, or peritoneal cancer.
Timeline
- Start
- 1999-06
- Primary completion
- 2000-07
- Completion
- 2000-07
Publications
- Results Buller RE, Shahin MS, Horowitz JA, Runnebaum IB, Mahavni V, Petrauskas S, Kreienberg R, Karlan B, Slamon D, Pegram M. Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. Cancer Gene Ther. 2002 Jul;9(7):567-72. doi: 10.1038/sj.cgt.7700473.
- Results Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T, Petrauskas S, Kreienberg R, Slamon D, Pegram M. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 2002 Jul;9(7):553-66. doi: 10.1038/sj.cgt.7700472.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SCH-58500 | Gene therapy (AAV / viral vector) | 7.5e+10 unknown | Other |
| Subject | SCH-58500 | Gene therapy (AAV / viral vector) | 7.5e+12 unknown | Other |
| Subject | SCH-58500 | Gene therapy (AAV / viral vector) | 2.5e+13 unknown | Other |
| Subject | SCH-58500 | Gene therapy (AAV / viral vector) | 7.5e+13 unknown | Other |